ARVN

#2810
Arvinas, Inc. - Common Stock
9.2 0 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
9.20
9.20
Intervallo Annuale
6.97
14.51
Variazione giornaliera
+0.22%
Variazione Mensile
+13.58%
Variazione di 6 mesi
-28.40%
Variazione Annuale
-1.08%
Chiusura Precedente
9.1 8
Open
9.2 0
Minimo
9.2 0
Massimo
9.2 0
Volume
119
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
ARVINAS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ARVINAS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ARVINAS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ARVINAS, INC. quarterly report, Q1 FY2026
10-Q

ARVINAS, INC. current report, Q2 FY2026

Full document

Arvinas, Inc. (ARVN) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Arvinas, Inc. on June 22, 2026. The report discloses the departure of a senior executive officer, Noah Berkowitz, M.D., Ph.D., who served as the Company's Chief Medical Officer.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.

Material Changes

The primary material change is the resignation of Dr. Noah Berkowitz as Chief Medical Officer, effective July 3, 2026. The Company has initiated a search for a replacement. A Separation Agreement was executed on June 22, 2026, outlining the terms of his departure.

Outlook, Risks, and Unusual Items

Separation Terms: Dr. Berkowitz is entitled to the following severance benefits subject to the non-revocation of the Separation Agreement:

  • Continued base salary payments for nine months.
  • Payment of health coverage premiums for up to nine months.
  • Acceleration of vesting for Restricted Stock Units (RSUs) that would have vested on or before May 9, 2027, under the 2018 Stock Incentive Plan or Nasdaq Listing Rule 5635(c).
  • Forfeiture of all other RSU awards not accelerated.

Legal and Operational Risks: The agreement includes a release of claims by Dr. Berkowitz in the Company's favor, as well as obligations regarding confidentiality, cooperation, and non-disparagement. The full text of the Separation Agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.

Investor Verification Checklist

  • Verify the exact number of RSUs accelerated for Dr. Berkowitz and the associated valuation impact once the Form 10-Q is filed.
  • Monitor the timeline for the appointment of a new Chief Medical Officer to assess potential impacts on clinical development programs.
  • Review the full Separation Agreement in the upcoming Form 10-Q for any additional covenants or conditions not detailed in this 8-K.

Notizie